SpectraCure AB Year-end report 1 January – 31 December 2018

Fourth quarter (1 October – 31 December 2018)

  • Net sales for the quarter amounted to TSEK 0 (0).
  • Operating profit (EBIT) was TSEK -3 249 (-2 599).
  • Operating cash flow was TSEK -3 806 (-2 632).
  • Profit after tax amounted to TSEK -3 242 (-2 599).
  • Corresponding to SEK -0,04 (-0,04) per share.

Full-year (1 January – 31 December 2018)

  • Net sales for the period amounted to MSEK 0 (0).
  • Operating profit (EBIT) was TSEK -11 821 (-8 535).
  • Operating cash flow was TSEK -10 864 (-9 095).
  • Profit after tax amounted to TSEK -11 814 (-8 535).
  • Corresponding to SEK -0,16 (-0,14) per share.

For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46(0) 8 503 000 50 

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on February 15th, 2019.

Release

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope